Snapshot from Sep 18, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory regulatory approval

Knight Therapeutics TAVALISSE Colombia Approval

Analysis based on 7 articles · First reported Sep 01, 2026 · Last updated Sep 01, 2026

Sentiment
10
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The approval is a positive regulatory milestone for Knight Therapeutics, potentially expanding its revenue base in Latin America and strengthening its product portfolio. It may also benefit Bora Pharmaceuticals through increased royalties or milestone payments, though the immediate market impact is likely modest given the drug's niche indication.

Pharmaceuticals

Knight Therapeutics Inc. announced on September 1, 2026, that it received regulatory approval from Colombia — National Food and Drug Surveillance Institute, Colombia's health regulatory agency, for TAVALISSE (fostamatinib disodium hexahydrate) for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response, loss of response, or intolerance to prior treatment with corticosteroids and intravenous immunoglobulin. This approval marks a significant step in expanding access to the drug in Latin America, following Knight's 2022 agreement with Bora Pharmaceuticals for exclusive commercialization rights in the region. Knight has submitted TAVALISSE for approval in Brazil, Colombia, Mexico, Argentina, and Paraguay, launched it in Mexico in May 2026, and expects launches in Brazil in Q4 2026 and Colombia in H1 2027.

stock
Knight Therapeutics received regulatory approval from Colombia — National Food and Drug Surveillance Institute for TAVALISSE in Colombia, advancing its Latin American commercialization strategy and potentially boosting future revenues.
Importance 100.0 Sentiment 20.0
stock
Bora Pharmaceuticals, the licensor of TAVALISSE, may benefit from increased sales and royalties as Knight expands the drug's availability in Latin America.
Importance 70.0 Sentiment 15.0
govactor
Colombia — National Food and Drug Surveillance Institute, Colombia's health regulatory agency, granted approval for TAVALISSE, fulfilling its role in evaluating and authorizing pharmaceutical products for the Colombian market.
Importance 60.0 Sentiment 0.0
cnt
Colombia gains a new treatment option for chronic ITP patients, potentially improving healthcare outcomes and expanding access to innovative therapies.
Importance 50.0 Sentiment 10.0
cnt
Brazil is a key market where TAVALISSE is under regulatory review, with a planned launch in Q4 2026, potentially expanding Knight's presence.
Importance 40.0 Sentiment 10.0
cnt
Mexico, where TAVALISSE was launched in May 2026, represents an active market for Knight, contributing to regional revenue growth.
Importance 40.0 Sentiment 10.0
per
Samira Sakhia, as President and CEO of Knight Therapeutics, announced the approval and highlighted its significance for the company's Latin American expansion.
Importance 30.0 Sentiment 0.0
cnt
Canada is the headquarters of Knight Therapeutics, and the company's success in Latin America may positively reflect on its home market operations.
Importance 20.0 Sentiment 5.0
cnt
The United States is where TAVALISSE is already marketed, and the Colombian approval may have indirect benefits for Rigel's overall product performance.
Importance 20.0 Sentiment 5.0
cnt
Argentina is one of the countries where TAVALISSE has been submitted for regulatory approval, part of Knight's broader Latin American strategy.
Importance 20.0 Sentiment 5.0
cnt
Paraguay is another market where TAVALISSE has been submitted for approval, reflecting Knight's regional expansion efforts.
Importance 20.0 Sentiment 5.0
loc
Europe, where TAVALISSE is sold under the brand TAVLESSE, represents an established market, and the Latin American approvals may complement global sales.
Importance 20.0 Sentiment 5.0
Colombia related ↔ Brazil
Colombia related ↔ Mexico
Colombia related ↔ Canada
Colombia related ↔ United States
Colombia related ↔ Argentina
Brazil related ↔ Mexico
Brazil related ↔ Canada
Brazil related ↔ United States
Brazil related ↔ Argentina
Mexico trade partners ↔ Canada Mexico maintains a major economic partnership with Canada, anchored by their mutual participation in the USMCA. The coun
Mexico related ↔ United States
Mexico related ↔ Argentina
Canada trade rivals ↔ United States Canada views the United States as a strained partner and trade rival, facing significant tariffs and renegotiation of tr
Canada related ↔ Argentina
United States related ↔ Argentina
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.